RS20050523A - Pde4 inhibotors for the treatment of neoplasms of lymphoid cells - Google Patents

Pde4 inhibotors for the treatment of neoplasms of lymphoid cells

Info

Publication number
RS20050523A
RS20050523A YUP-2005/0523A YUP20050523A RS20050523A RS 20050523 A RS20050523 A RS 20050523A YU P20050523 A YUP20050523 A YU P20050523A RS 20050523 A RS20050523 A RS 20050523A
Authority
RS
Serbia
Prior art keywords
neoplasms
treatment
lymphoid cells
inhibotors
pde4
Prior art date
Application number
YUP-2005/0523A
Other languages
English (en)
Inventor
Jurgen Braunger
Christian Schudt
Armin Hatzelmann
Hermann Tenor
Volker Gekeler
Karl Sanders
Enrico Garattini
Original Assignee
Altana Pharma Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag., filed Critical Altana Pharma Ag.,
Publication of RS20050523A publication Critical patent/RS20050523A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na korišćenje nekih PDE4 inhibitora, pojedinačno ili u kombinaciji sa jednim ili više agenasa za indukciju diferencijacije i/ili nekim agensom koji je efikasan u podizanju intracelularne koncentracije cAMP ili stabilnog analoga cAMP u dobijanju farmaceutskih kompozicija za tretman neoplazmi limfocitnih ćelija.
YUP-2005/0523A 2003-01-14 2004-01-14 Pde4 inhibotors for the treatment of neoplasms of lymphoid cells RS20050523A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03000787 2003-01-14
PCT/EP2004/000196 WO2004062671A2 (en) 2003-01-14 2004-01-14 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells

Publications (1)

Publication Number Publication Date
RS20050523A true RS20050523A (en) 2007-09-21

Family

ID=32695591

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0523A RS20050523A (en) 2003-01-14 2004-01-14 Pde4 inhibotors for the treatment of neoplasms of lymphoid cells

Country Status (10)

Country Link
US (1) US20060148804A1 (sr)
EP (1) EP1587512A2 (sr)
JP (1) JP2006515367A (sr)
AU (1) AU2004204355B2 (sr)
CA (1) CA2512819A1 (sr)
HR (1) HRP20050699A2 (sr)
IS (1) IS7970A (sr)
PL (1) PL378247A1 (sr)
RS (1) RS20050523A (sr)
WO (1) WO2004062671A2 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2178369A4 (en) * 2007-07-17 2010-12-15 Combinatorx Inc TREATMENTS OF PROLIFERATIVE DISORDERS OF LYMPHOCYTES B
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
AR086915A1 (es) * 2011-06-17 2014-01-29 Nycomed Gmbh Derivados de ftalazinona-pirrolopirimidinacarboxamida y composiciones farmaceuticas que los contiene
AR089232A1 (es) * 2011-12-16 2014-08-06 Chiesi Farma Spa Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399649B1 (en) * 1998-09-24 2002-06-04 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
US6232121B1 (en) * 1999-06-03 2001-05-15 Hugh S. Keeping Methods for the production of biologically active agents contained in an extracellular matrix
WO2001012953A1 (fr) * 1999-08-10 2001-02-22 Wago Co., Ltd. Boulon d'ancrage et son procede de fabrication
MXPA02001830A (es) * 1999-08-21 2002-08-12 Byk Gulden Lomberg Chem Fab Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor.
PL354979A1 (en) * 1999-10-25 2004-03-22 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
EP1289557B1 (en) * 2000-06-06 2006-07-12 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
MXPA03007310A (es) * 2001-02-15 2003-12-04 Altana Pharma Ag Derivados de ftalazinona piperidino como inhibidores pde4.
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods

Also Published As

Publication number Publication date
WO2004062671A3 (en) 2005-01-27
PL378247A1 (pl) 2006-03-20
HRP20050699A2 (en) 2006-11-30
EP1587512A2 (en) 2005-10-26
WO2004062671A2 (en) 2004-07-29
AU2004204355A1 (en) 2004-07-29
US20060148804A1 (en) 2006-07-06
AU2004204355B2 (en) 2009-12-17
IS7970A (is) 2005-08-05
JP2006515367A (ja) 2006-05-25
CA2512819A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
MY143795A (en) Tetrahydropyridoindole derivatives
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
TW200744639A (en) Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
MXPA06012640A (es) Compuestos de morfolina.
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MY144318A (en) Methods of treating hiv infection.
MX2009013810A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos.
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MY161991A (en) Proteasome inhibitors
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
IL183252A0 (en) Solid formulations of liquid biologically active agents
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
IL179106A0 (en) Compounds and compositions for delivering active agents
IL179378A0 (en) Method and formulation for transdermal delivery of immunologically active agents
HRP20050699A2 (en) Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
TW200628468A (en) Bicyclononene derivatives
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
EP1667656A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING BIOLOGICALLY ACTIVE AGENTS
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln